Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Persistent SARS-CoV-2 infection: significance and implications
Heather Machkovech, Anne M. Hahn, Jacqueline Garonzik‐Wang, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 7, pp. e453-e462
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

A SARS-CoV-2 mucosal nanovaccine based on assembly of maltodextrin, STING agonist and polyethyleneimine
Yu Tian, Liang Hu, Qingrui Huang, et al.
International Journal of Biological Macromolecules (2025), pp. 139395-139395
Closed Access
Evaluation of Inflammatory Markers and Clinical Outcomes in COVID-19 Patients with Concurrent Clostridioides difficile Infection: A Comparative Cohort Analysis
Flavia Ignuta, Adrian Vlad, Teodor Cerbulescu, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 111-111
Open Access
Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
Ricardo da Silva Antunes, Vicente Fajardo-Rosas, Esther Dawen Yu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review
Caroline Hirsch, Nina Kreuzberger, Nicole Skoetz, et al.
Journal of Antimicrobial Chemotherapy (2025)
Open Access
Adaptive evolution of SARS-CoV-2 during a persistent infection for 521 days in an immunocompromised patient
Hanno Schmidt, Luca A. Schick, Jürgen Podlech, et al.
npj Genomic Medicine (2025) Vol. 10, Iss. 1
Open Access
Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2
Marta Colaneri, Marta Canuti, G Torrigiani, et al.
Infectious Diseases and Therapy (2025)
Open Access
Refractory pneumonia due to persistent SARS-CoV-2 infection in an immunocompromised host successfully treated with extended course nirmatrelvir/ritonavir
Shiro Sonoda, Sho Shimada, Atsushi Sawada, et al.
Deleted Journal (2025)
Open Access
Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report
Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, et al.
Journal of Pharmaceutical Health Care and Sciences (2025) Vol. 11, Iss. 1
Open Access
Longitudinal Assessment of Pulmonary Involvement and Prognosis in Different Subtypes of COVID-19 Patients After One Year Using Low-Dose CT: A Prospective Observational Study
Jinyang Zhao, Liang Dong, Xue Jiao, et al.
Academic Radiology (2025)
Closed Access
The trend of phylogenetic and epitope variations of SARS-CoV-2 Omicron sub-lineages in Iran
Mehdi Shabani, Ahmad Nejati, Jila Yavarian, et al.
Frontiers in Microbiology (2025) Vol. 15
Open Access
Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases
Tonino Alonzi, Alessandra Aiello, Michela Sali, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117153-117153
Open Access | Times Cited: 3
Re: Persistent COVID-19 in immunocompromised patients—Israeli Society of Infectious Diseases consensus statement on diagnosis and management by Meijer et al.
Alberto Enrico Maraolo, Nicola Schiano Moriello, Ivan Gentile
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 9, pp. 1209-1210
Closed Access | Times Cited: 2
Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship
Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 6, pp. 1404-1407
Closed Access | Times Cited: 2
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis
Maria Mazzitelli, Alberto Enrico Maraolo, Claudia Cozzolino, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Navigating the Long Haul: A Comprehensive Review of Long-COVID Sequelae, Patient Impact, Pathogenesis, and Management
Nishant Rathod, Sunil Kumar, Roma Chavhan, et al.
Cureus (2024)
Open Access | Times Cited: 1
SARS-CoV-2 reinfection rate before and after VOC Omicron emergence: a retrospective study in Brazil
Paula Luize Camargos Fonseca, Frederico Scott Varella Malta, Isabela Braga-Paz, et al.
Brazilian Journal of Microbiology (2024)
Closed Access | Times Cited: 1
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19
Kanal Singh, Joseph M. Rocco, Véronique Nussenblatt
Seminars in Hematology (2024) Vol. 61, Iss. 5, pp. 321-332
Closed Access | Times Cited: 1
Long‐term persistence of mitochondrial dysfunctions after viral infections and antiviral therapies: A review of mechanisms involved
Laëtitia Gay, Valérie Desquiret‐Dumas, Nicolas Nagot, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 9
Open Access | Times Cited: 1
In Silico Design of miniACE2 Decoys with In Vitro Enhanced Neutralization Activity against SARS-CoV-2, Encompassing Omicron Subvariants
Jenny Andrea Arévalo-Romero, Gina López-Cantillo, Sara Moreno-Jiménez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10802-10802
Open Access | Times Cited: 1
Clinical Features and Predictive Nomogram for Fatigue Sequelae in Non-severe Patients Infected with SARS-CoV-2 Omicron Variant in Shanghai, China
Xiaolei Shen, Yuhan Jiang, Shenjie Li, et al.
Brain Behavior & Immunity - Health (2024) Vol. 42, pp. 100889-100889
Open Access | Times Cited: 1
Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients
Chiara Sepulcri, Claudia Bartalucci, Małgorzata Mikulska
Current Opinion in Infectious Diseases (2024) Vol. 37, Iss. 6, pp. 506-517
Closed Access | Times Cited: 1
Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC
Kaori Sano, Kei Miyakawa, Hideaki Kato, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
The consequences of SARS-CoV-2 within-host persistence
Alex Sigal, Richard A. Neher, Richard Lessells
Nature Reviews Microbiology (2024)
Closed Access | Times Cited: 1
Dual therapy with remdesivir plus extended nirmatrelvir/ritonavir in immunocompromised and critically ill patient with suspected persistent COVID-19 infection: Case report
Arturo Gámiz Rejano, Teresa López-Viñau, Charlotte Martin, et al.
Medicina Intensiva (English Edition) (2024)
Closed Access | Times Cited: 1
Intrahost evolution leading to distinct lineages in the upper and lower respiratory tracts during SARS-CoV-2 prolonged infection
Majdouline El Moussaoui, Sébastien Bontems, Cécile Meex, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top